Onxeo Plans Clinical Trials For Three Phase III Orphan Oncologics
This article was originally published in The Pink Sheet Daily
The year-old pan-European biotech is targeting advanced liver cancer, severe mucositis and the rare cancer, peripheral T-cell lymphoma, for its first products in the orphan oncology niche.
You may also be interested in...
With Spectrum’s Beleodaq’s accelerated approval for peripheral T-cell lymphoma, FDA rolls Folotyn accelerated approval requirement into one post-marketing trial that will provide answers on both drugs – including which is better against standard of care.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.